---
title: "Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Humanistic burden and health-related quality of life"
description: "Formulary evidence on Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Humanistic burden and health-related quality of life. Topics: Quality of life, sleep, and work impairment in adults with CSU persisting 12 months or more despite treatment, Novartis-funded; Adults with self-reported physician-diagnosed CSU, 2019 National Health and Wellness Survey: utilities, DLQI, anxiety, depression, and work impairment, Novartis-funded; CSU compared with atopic dermatitis and psoriasis, 2019 US National Health and Wellness Survey; Chronic urticaria compared with psoriasis in France, Germany, Italy, Spain, and the United Kingdom, supported by Novartis and Genentech; 5 further topics. 9 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description/humanistic-burden-and-health-related-quality-of-life"
published: "2026-11-18T22:38:31-05:00"
modified: "2026-11-18T22:38:31-05:00"
---

# Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Humanistic burden and health-related quality of life

<a id="heading-2.2.1.8.1"></a>

## 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

### Quality of life, sleep, and work impairment in adults with CSU persisting 12 months or more despite treatment, Novartis-funded

> “This international observational study assessed a cohort of 673 adult patients with CSU whose symptoms persisted for ≥12 months despite treatment.”
> “Almost 50% of patients had moderate‐to‐severe disease activity as reported by Urticaria Activity Score. Mean (SD) Dermatology Life Quality Index and Chronic Urticaria Quality of Life Questionnaire scores were 9.1 (6.62) and 33.6 (20.99), respectively. Chronic spontaneous urticaria markedly interfered with sleep and daily activities. Angioedema in the previous 12 months was reported by 66% of enrolled patients and significantly affected HRQoL. More than 20% of patients reported ≥1 hour per week of missed work; productivity impairment was 27%. These effects increased with increasing disease activity.”
> “The EQ‐5D‐3L domains for which patients most frequently reported moderate or extreme problems were pain/discomfort (63.2% of patients), anxiety/depression (47.4%), and usual activities (34.2%) (Figure 3C).”
> “Mean DLQI scores in this study suggest that CSU has a moderate impact on patients’ HRQoL,35 which is greater than previously thought; further, more than 40% had DLQI scores of 10 or greater, which, in psoriasis, justifies the initiation of a biologic.”
> “This study was funded by Novartis Pharma AG.”

Source: [Maurer et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5724512/)

<a id="topic-2.2.1.8.1-2"></a>

### Adults with self-reported physician-diagnosed CSU, 2019 National Health and Wellness Survey: utilities, DLQI, anxiety, depression, and work impairment, Novartis-funded

> “Data from respondents with physician-diagnosed CSU were collected from the 2019 National Health and Wellness Survey (NHWS).”
> “Among 74,994 respondents, 815 reported physician-diagnosed chronic urticaria, with 635 (77.9%) having CSU.”
> “The mean (SD) SF-6D and EQ-5D health utility scores were 0.54 (0.14) and 0.62 (0.34), respectively. The mean (SD) DLQI score was 13.8 (11.2), with more than 74.0% of respondents reporting anxiety (GAD-7 ≥5) and depression (PHQ-9 ≥5). Mean percent (SD) scores for absenteeism, presenteeism, overall work impairment, and activity impairment were 36.5% (26.1), 67.2% (34.9), 73.1% (34.2), and 62.6% (34.1), respectively.”
> “The mean (SD) DLQI score was 13.8 (11.2), with 54.2% of respondents having a score >10. More than one-third (36.5%) of respondents had a DLQI score between 21 and 30, indicating an extremely large effect on the patient's life (Fig. 4).”
> “This research was funded by Novartis Pharma AG, Basel, Switzerland.”

Source: [Soong et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12296495/)

<a id="topic-2.2.1.8.1-3"></a>

### CSU compared with atopic dermatitis and psoriasis, 2019 US National Health and Wellness Survey

> “This retrospective, cross-sectional study used real-world data from adult respondents from the 2019 US National Health and Wellness Survey (NHWS).”
> “Mean (standard error [SE]) MCS and PCS scores were lower (worse) among respondents with physician-diagnosed CSU vs. AD and PSO, respectively: MCS: 41.3 (0.6) vs. 44.8 (0.5) vs. 45.3 (0.2); PCS: 42.1 (0.5) vs. 47.8 (0.4) vs. 47.7 (0.2); all p < 0.001.”
> “Respondents with CSU reported higher (p < 0.001) work and activity impairment and HCRU vs. respondents with AD or PSO.”

Source: [Soong et al. (2025a)](https://pubmed.ncbi.nlm.nih.gov/40556432/)

<a id="topic-2.2.1.8.1-4"></a>

### Chronic urticaria compared with psoriasis in France, Germany, Italy, Spain, and the United Kingdom, supported by Novartis and Genentech

> “This retrospective cross‐sectional analysis compared data from adult patients with chronic urticaria (CU), used as a proxy for CSU, and PsO from the National Health and Wellness Survey in France, Germany, Italy, Spain and the United Kingdom.”
> “This analysis included 769 CU and 7857 PsO (26.9% moderate/severe) patients. Following adjustment for covariates, CU patients showed a greater health‐related quality of life (HRQoL) impairment vs. overall PsO (MCS: −2.4, PCS: −1.6, SF‐6D: −0.03; all P < 0.001). CU patients showed a higher risk of anxiety, depression and sleep difficulties [odds ratio (OR): 1.63, 1.34 and 1.56, respectively; all P < 0.01] and greater healthcare resource use vs. overall PsO.”
> “Burden of illness in CU is higher than PsO of all severities but similar to that observed in moderate/severe PsO.”
> “The study was supported by Novartis Pharma AG, Basel, Switzerland, and Genentech, Inc., South San Francisco, CA, USA.”

Source: [Balp et al. (2018a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6084337/)

<a id="topic-2.2.1.8.1-5"></a>

### Patient-reported burden by disease control in a multinational online survey, Novartis-funded

> “A multinational, cross-sectional online survey was completed by patients with chronic urticaria (CU) and physicians treating CU.”
> “A total of 582 patients with CSU (62% women; mean [standard deviation, SD] age: 42.2 [11.9] years) completed the online survey. Patients reported a mean (SD) diagnostic delay of 2 (5.4) years and saw 6.1 (8.9) physicians. The majority (79%) of patients were on antihistamines, of which 84% were inadequately controlled (UCT score of < 12) and reported a significantly higher negative impact of CSU on the HRQoL domains than adequately controlled patients, with the highest impact on mental and emotional well-being and social life and intimate relationships. More than half (55%) of the patients experienced angioedema with a mean (SD) of 7.7 (14.0) episodes per year. In addition, sleeping problems (62%), pain (55%) and fatigue (49%) were frequently reported physical symptoms during an exacerbation.”
> “This study, and the journal’s Rapid Service and Open Access Fees, were funded by Novartis Pharma AG, Basel, Switzerland.”

Source: [Weller et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11909366/)

<a id="topic-2.2.1.8.1-6"></a>

### Sex and age differences in angioedema, sleep disturbance, and quality of life in the CURE registry

> “We analysed Chronic Urticaria Registry (CURE) data, an international real‐world registry for patients with chronic urticaria.”
> “Across 4136 CSU patients (from 58 sites across 29 countries), 2994 (72.4%) were female.”
> “Compared with males, females showed higher rates of angioedema (59.6 vs. 51.7%; p < 0.001), systemic symptoms (34.6 vs. 25.4%; p < 0.001), sleep disturbance (38.9 vs. 32.5%; p < 0.001), QoL impairment (CU‐Q2oL score 32 vs. 27.7; p < 0.001) and lower rates of urticaria control than males in all medication categories (p < 0.05 for all).”
> “The disease was especially more burdensome and refractory in females aged 51–65 years than males, evidenced by more angioedema and systemic symptoms, worse QoL, lower UCT scores and more emergency visits (p < 0.05 for all).”

Source: [Kocatürk et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12723574/)

<a id="topic-2.2.1.8.1-7"></a>

### Quality of life of chronic urticaria outpatients on the Nottingham health profile

> “One hundred and forty-two out-patients completed self-administered questionnaires: a disease-specific, purpose designed questionnaire, and the Nottingham health profile (NHP).”
> “The NHP part I scores showed restriction in the areas of mobility, sleep, energy, and demonstrated pain, social isolation and altered emotional reactions.”

Source: [O'Donnell et al. (1997)](https://pubmed.ncbi.nlm.nih.gov/9068731/)

<a id="topic-2.2.1.8.1-8"></a>

### Review of the global burden of chronic urticaria: quality of life, anxiety and depression, and work

> “Here we review the impact of CU on different aspects of patients' quality of life and the burden of this chronic disease for the patient and society.”
> “CU may have a strong impact on health-related quality of life (HRQoL), particularly when CSU is associated with angio-oedema and/or CIndU (Dermatology Life Quality Index > 10 in 30% of patients). Comorbidities, such as anxiety and depression, which are present in more than 30% of patients with CSU, compound HRQoL impairment.”
> “Severe pruritus and the unpredictable occurrence of weals and angio-oedema are responsible for sleep disorders; sexual dysfunction; limitations on daily life, work and sports activities; interfering with life within the family and in society; and patients' performance at school and work (6% absenteeism and 25% presenteeism).”

Source: [Gonçalo et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32956489/)

<a id="topic-2.2.1.8.1-9"></a>

### Narrative review of the overall burden of CSU

> “This narrative review synthesizes current evidence on the overall burden of CSU, encompassing epidemiology, clinical manifestations, humanistic impact, cumulative life course impairment, and economic costs.”
> “CSU markedly disrupts quality of life through sleep disturbance, pruritus, emotional distress, psychiatric comorbidity, impaired social and occupational functioning, and stigma, with effects extending to children, caregivers, and family members.”

Source: [Kocatürk et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/41913980/)

## Related pages
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Terms and abbreviations](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations.md)
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Product information and disease description](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Clinical evidence](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Economic information and modeling report](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: References](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references.md)
